The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma
- PMID: 15180922
- DOI: 10.1152/ajprenal.00424.2003
The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma
Abstract
The majority of kidney cancers are caused by the mutation of the von Hippel-Lindau (VHL) tumor suppressor gene. VHL protein (pVHL) is part of an E3 ubiquitin ligase complex called VEC that is composed of elongin B, elongin C, cullin 2, NEDD8, and Rbx1. VEC targets a hypoxia-inducible factor (HIF) transcription factor for ubiquitin-mediated destruction selectively in the presence of oxygen. In the absence of wild-type pVHL, as in VHL patients or in the majority of sporadic clear cell renal cell carcinomas, HIF-responsive genes are inappropriately activated even under normoxia. Recent insights into the molecular mechanisms regulating the function of pVHL, and thereby HIF, in the context of kidney cancer are the focus of this review.
Similar articles
-
The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.Oncogene. 2001 Aug 16;20(36):5067-74. doi: 10.1038/sj.onc.1204602. Oncogene. 2001. PMID: 11526493
-
The von Hippel-Lindau tumor suppressor gene and kidney cancer.Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6290S-5S. doi: 10.1158/1078-0432.CCR-sup-040025. Clin Cancer Res. 2004. PMID: 15448019 Review.
-
Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.Cancer Res. 2002 Jul 1;62(13):3803-11. Cancer Res. 2002. PMID: 12097293
-
Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.Am J Nephrol. 2004 Jan-Feb;24(1):1-13. doi: 10.1159/000075346. Epub 2003 Dec 3. Am J Nephrol. 2004. PMID: 14654728 Review.
-
Role of VHL gene mutation in human cancer.J Clin Oncol. 2004 Dec 15;22(24):4991-5004. doi: 10.1200/JCO.2004.05.061. J Clin Oncol. 2004. PMID: 15611513 Review.
Cited by
-
Recent Advances in the Medical Treatment of Recurrent or Metastatic Renal Cell Cancer.Drugs. 2017 Jan;77(1):17-28. doi: 10.1007/s40265-016-0665-1. Drugs. 2017. PMID: 27995579 Review.
-
Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.Oncotarget. 2012 Nov;3(11):1472-82. doi: 10.18632/oncotarget.561. Oncotarget. 2012. PMID: 23178531 Free PMC article.
-
Tonantzitlolone cytotoxicity toward renal cancer cells is PKCθ- and HSF1-dependent.Oncotarget. 2015 Oct 6;6(30):29963-74. doi: 10.18632/oncotarget.4676. Oncotarget. 2015. PMID: 26298773 Free PMC article.
-
Meta-analysis identifies NF-κB as a therapeutic target in renal cancer.PLoS One. 2013 Oct 7;8(10):e76746. doi: 10.1371/journal.pone.0076746. eCollection 2013. PLoS One. 2013. PMID: 24116146 Free PMC article.
-
VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1α/VEGF and β-catenin/Tcf-4 signaling.Neuro Oncol. 2012 Aug;14(8):1026-36. doi: 10.1093/neuonc/nos122. Epub 2012 May 30. Neuro Oncol. 2012. PMID: 22649212 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous